{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:51:38Z","timestamp":1794307898052,"version":"4.9.0"},"reference-count":14,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>DIPSS-plus (the Dynamic International Prognostic Scoring System-plus) includes 8 risk factors for survival in primary myelofibrosis. In the present study of 884 karyotypically annotated patients with primary myelofibrosis, we sought to identify 1 or 2 parameters that can reliably predict death in the first 2 years of disease. After a median of 8.2 years from time of referral to the Mayo Clinic, 564 deaths (64% of patients in the study) had been recorded. Risk factors associated with &gt; 80% 2-year mortality included monosomal karyotype, inv(3)\/i(17q) abnormalities, or any 2 of the following: circulating blasts &gt; 9%, leukocytes \u2265 40 \u00d7 109\/L, or other unfavorable karyotype. Patients with any 1 of these risk profiles (n = 52) displayed significantly shorter overall survival than those otherwise belonging to a high-risk category per DIPSS-plus (n = 298); respective median survivals were 9 and 23 months (hazard ratio 2.2, 95% confidence interval 1.6-3.1; P &lt; .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches.<\/jats:p>","DOI":"10.1182\/blood-2011-08-371096","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T08:09:34Z","timestamp":1314864574000},"page":"4595-4598","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients"],"prefix":"10.1182","volume":"118","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitina","family":"Jimma","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhee","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Hematopathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Van Dyke","sequence":"additional","affiliation":[{"name":"Cytogenetics, Mayo Clinic, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Caramazza","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111808050667500_B1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111808050667500_B2","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","article-title":"Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.","volume":"117","author":"Vaidya","year":"2011","journal-title":"Blood"},{"issue":"33","key":"2019111808050667500_B3","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis.","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111808050667500_B4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"issue":"22","key":"2019111808050667500_B5","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1182\/blood-2009-12-255943","article-title":"Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients.","volume":"115","author":"Morel","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111808050667500_B6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111808050667500_B7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111808050667500_B8","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.","volume":"114","author":"Kroger","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111808050667500_B9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111808050667500_B10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis.","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111808050667500_B11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111808050667500_B12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111808050667500_B13","unstructured":"Tefferi\n              A\n            \n            \n              Jimma\n              T\n            \n            \n              Sulai\n              N\n            \n            \n          \n          IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.\n          Leukemia\n          [published online ahead of print September 13, 2011] doi:10.1038\/leu.2011.253. Available at: http:\/\/www.nature.com\/leu\/journal\/vaop\/ncurrent\/full\/leu2011253a.html"},{"issue":"18","key":"2019111808050667500_B14","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/17\/4595\/1463380\/zh804311004595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/17\/4595\/1463380\/zh804311004595.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:21:45Z","timestamp":1574065305000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/17\/4595\/29040\/Predictors-of-greater-than-80-2year-mortality-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,27]]},"references-count":14,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2011,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-08-371096","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,27]]}}}